Valuation: Freenome, Inc.

Market Cap 1.3B 1.13B 1.06B 963M 1.81B 125B 1.84B 12.41B 4.86B 62.48B 4.9B 4.79B 208B P/E 2024
-0.95x
P/E 2025 -1.57x
Enterprise Value 1.4B 1.21B 1.13B 1.03B 1.94B 134B 1.97B 13.31B 5.21B 67.02B 5.25B 5.14B 223B EV / Sales 2024
18.7x
EV / Sales 2025 6.94x
Free-Float
96.46%
Yield 2024 *
-
Yield 2025 -
1 day-0.43%
1 week+3.68%
Current month+3.68%
1 month-3.67%
3 months+4.33%
6 months-16.89%
Current year-11.28%
1 week 11.4
Extreme 11.4
13.17
1 month 9.97
Extreme 9.97
14.26
Current year 9.95
Extreme 9.95
14.47
1 year 9.95
Extreme 9.95
14.47
3 years 9.95
Extreme 9.95
14.47
5 years 9.95
Extreme 9.95
14.47
10 years 9.95
Extreme 9.95
14.47
Date Insider Type Main position Quantity % Market Cap.
7/20/26 Other

Chief Executive Officer

835,791 0.3889%
7/20/26 Conversion -30,000 1.3913%
7/20/26
RA Capital Management LP
OtherCompany 750,000 0.3490%
Change 5-day change 1-year change 3-year change Capi.($)
-0.43%+3.68%+9.37% - 1.3B
+0.12%-0.64%+89.95%+298.23% 3.95B
+2.01%-10.89%+39.25%+71.69% 3.32B
+1.72%+11.99%+178.43%+2.90% 3.16B
+2.34%-0.66%+291.72%+430.66% 2.34B
-2.12%-0.45%-22.91%-27.87% 2.31B
+0.78%+11.25%+15.23%+51.65% 1.04B
-0.35%-8.83%+117.62%-45.38% 849M
+29.91%+22.82%-6.81%+369.61% 616M
-0.69%+5.65%-34.88%-1.51% 566M
Average +3.33%+0.24%+67.70%+127.77% 1.95B
Weighted average by Cap. +1.60%-1.08%+91.72%+143.87%

Financials

2024 2025
Net sales 2.88M 2.49M 2.34M 2.13M 4M 275M 4.06M 27.41M 10.73M 138M 10.82M 10.58M 459M 30.41M 26.26M 24.66M 22.45M 42.18M 2.91B 42.79M 289M 113M 1.46B 114M 112M 4.85B
Net income -274M -237M -223M -203M -381M -26.23B -386M -2.61B -1.02B -13.14B -1.03B -1.01B -43.73B -219M -189M -178M -162M -304M -20.97B -309M -2.09B -816M -10.5B -823M -806M -34.96B
Net Debt -36.95M -31.91M -29.96M -27.28M -51.25M -3.53B -51.99M -351M -138M -1.77B -139M -136M -5.89B 94.96M 82.01M 77M 70.11M 132M 9.08B 134M 903M 353M 4.55B 356M 349M 15.13B
Logo Freenome, Inc.
Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer. The Company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. The Company's development of SimpleScreen CRC for colorectal cancer screening, with clinical validation through the PREEMPT CRC Study, and a pipeline of tests for lung cancer and additional indications is designed to increase cancer screening participation. SimpleScreen CRC is a colorectal cancer screening test that uses a blood sample to look for signs of cancer and certain precancerous growths. The Company's platform integrates multiomics, artificial intelligence and machine learning to uncover complex biological signals associated with cancer.
Employees
363
Date Price Change Volume
26-08-17 US$13.00 +12.46% 1,893,009
26-08-14 US$11.56 -0.43% 775,653
26-08-13 US$11.61 +0.52% 611,513
26-08-12 US$11.55 -3.75% 1,407,601
26-08-11 US$12.00 +3.27% 1,060,687
  1. Stock Market
  2. Stocks
  3. FRNM Stock